New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:37 EDTALXNAlexion granted ODD to Soliris by FDA
Alexion Pharmaceuticals announced that the FDA has granted an orphan drug designation, or ODD, to Soliris, a first-in-class terminal complement inhibitor, for the prevention of delayed graft function, or DGF in renal transplant patients. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
07:06 EDTALXNAlexion backs FY15 non-GAAP EPS view of $4.70-$4.80, consensus $4.85
Backs FY15 revenue view of $2.6B-$2.62B, consensus $2.63B.
07:01 EDTALXNAlexion receives notification of PDUFA date extension for Kanuma
Subscribe for More Information
September 2, 2015
07:53 EDTALXNFDA PDUFA Date for Alexion's Asfotase Alfa is September 2, 2015
Subscribe for More Information
September 1, 2015
17:57 EDTALXNAlexion CEO sees slow sales uptake for Kanuma, Strensiq, Reuters says
In a Reuters interview following EU approval of the company's Strensiq and Kanuma treatments, Alexion CEO David Hallal said he expects a slow sales uptake for the two drugs, adding that boosting disease awareness and finding patients is a challenge. "It takes time to reach the patients and the physicians. When we launch, it's usually one patient at a time," said Hallal. The CEO also remarked that the company is targeting similar pricing between the U.S. and elsewhere. Reference Link
05:39 EDTALXNAlexion granted marketing authorization for Kanuma in EU
Subscribe for More Information
05:38 EDTALXNAlexion granted marketing authorization for Strensiq in EU
Subscribe for More Information
August 31, 2015
19:28 EDTALXNAlexion initiated with a Strong Buy at Raymond James
Target $225.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use